A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

• DOI: 10.1016/j.celrep.2021.109400
• Publication Date: 2021-06-29T04:33:04Z
• Authors: Traci L. Bricker; Tamarand L. Darling; Ahmed O. Hassan; Houda H. Harastani; Allison Soung; Xiaoping Jiang; Ya-Nan Dai; Haiyan Zhao; Lucas J. Adams; Michael J. Holtzman; Adam L. Bailey; James Brett Case; Daved H. Fremont; Robyn Klein; Michael S. Diamond; Adrianus C.M. Boon
• Keywords: Mesocricetus; Coronavirus

The development of an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent disease 2019 (COVID-19), is a global priority. Here, we compare protective capacity intranasal and intramuscular delivery chimpanzee adenovirus-vectored encoding prefusion stabilized spike protein (chimpanzee adenovirus [ChAd]-SARS-CoV-2-S) in Golden Syrian hamsters. Although immunization with ChAd-SARS-CoV-2-S induces robust spike-protein-specific antibodies capable neutralizing virus, antibody levels serum are higher hamsters vaccinated by compared to route. Accordingly, challenge SARS-CoV-2, ChAd-SARS-CoV-2-S-immunized protected less weight loss have reduced viral infection nasal swabs lungs, pathology inflammatory gene expression ChAd-control immunized Intranasal provides superior protection SARS-CoV-2 inflammation upper tract. These findings support administration candidate prevent infection, disease, possibly transmission.